The Letterer-Siwe Disease (Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis) drugs in development market research report provides comprehensive information on the therapeutics under development for Letterer-Siwe Disease (Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Letterer-Siwe Disease (Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis). Buy the report here.
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Letterer-Siwe Disease (Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis) and features dormant and discontinued products.
GlobalData tracks ten drugs in development for Letterer-Siwe Disease (Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis) by nine companies/universities/institutes. The top development phase for Letterer-Siwe Disease (Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis) is phase ii with eight drugs in that stage. The Letterer-Siwe Disease (Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis) pipeline has ten drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Letterer-Siwe Disease (Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis) pipeline products market are: Novartis, Betta Pharmaceuticals and Fochon Pharmaceutical.
The key targets in the Letterer-Siwe Disease (Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis) pipeline products market include Dual Specificity Mitogen Activated Protein Kinase Kinase 2 (ERK Activator Kinase 2 or MAPK/ERK Kinase 2 or MAP2K2 or EC 2.7.12.2), Dual Specificity Mitogen Activated Protein Kinase Kinase 1 (ERK Activator Kinase 1 or MAPK/ERK Kinase 1 or MAP2K1 or EC 2.7.12.2), and Serine/Threonine Protein Kinase B Raf (p94 or Proto Oncogene B Raf or v Raf Murine Sarcoma Viral Oncogene Homolog B1 or BRAF or EC 2.7.11.1).
See Also:
The key mechanisms of action in the Letterer-Siwe Disease (Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis) pipeline product include Dual Specificity Mitogen Activated Protein Kinase Kinase 2 (ERK Activator Kinase 2 or MAPK/ERK Kinase 2 or MAP2K2 or EC 2.7.12.2) Inhibitor with five drugs in Phase II. The Letterer-Siwe Disease (Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis) pipeline products include three routes of administration with the top ROA being Oral and two key molecule types in the Letterer-Siwe Disease (Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis) pipeline products market including Small Molecule, and Monoclonal Antibody.
Letterer-Siwe Disease (Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis) overview
Letterer-Siwe (LS) disease is an acute, disseminated, multisystem, often fatal type of Langerhans cell histiocytosis (LCH). It is one of the four recognized clinical syndromes of LCH the most severe, involving multiple organ systems such as the skin, bone marrow, spleen, liver, and lungs. LCH and all its subtypes are characterized by monoclonal migration and proliferation of specific dendritic cells.
For a complete picture of Letterer-Siwe Disease (Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis)’s pipeline drug market, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
